Anyone want any shares at 50 cents today?, page-2

When you ask. My view is when we get some detail on the methodology involved in the analytical assessment of the test kits. At the moment we are clueless as to what is involved... is it straightforward, is it complex, what resources are needed ( equipment, $$, etc) ?? Re-reading the last update it seems that RHY will do the analytics. I initially assumed Biotem would do the analytics, after all, they make the test kits so presumably are best set-up for testing them. Management silence on such obvious questions is not helping and the market is showing its displeasure in this uncertainty by continuing to further trash the share price. How hard is it for some commentary from management